Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
BACKGROUND
Induction therapy has been recently adopted for intestinal transplant.


METHODS
We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax) or Alemtuzumab (Campath-1H).


RESULTS
During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection.


CONCLUSIONS
Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.
Lauro
A
A
Liver and Multiorgan Transplant Unit, S.Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. augustola@yahoo.com
Amaduzzi
A
A
Dazzi
A
A
Ercolani
G
G
Zanfi
C
C
Golfieri
L
L
Grazi
G L
GL
Vivarelli
M
M
Cescon
M
M
Varotti
G
G
Del Gaudio
M
M
Ravaioli
M
M
Siniscalchi
A
A
Faenza
S
S
D'Errico
A
A
Di Simone
M
M
Pironi
L
L
Pinna
A D
AD
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000077561:Daclizumab; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007422:Intestines / Q000637:transplantation*; D008297:Male; D011184:Postoperative Period; D014184:Transplantation, Homologous; D014781:Viscera / Q000637:transplantation*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D000077561:Daclizumab